PROJECT HOPE AIRLIFT TO PANAMA OF $2 MIL. IN DRUGS/MEDICAL SUPPLIES
PROJECT HOPE AIRLIFT TO PANAMA OF $2 MIL. IN DRUGS/MEDICAL SUPPLIES began Jan. 11, with donations from 23 U.S. manufacturers. Items contributed include antibiotics, anesthetics, antibacterials, anticoagulants, anti-inflammatories and antihypertensives, as well as general medical supplies such as sutures, bandages and syringes. Among the drug companies participating in the relief effort are Abbott Labs; Bristol-Myers Squibb; Burroughs Wellcome; Johnson & Johnson (and subsidiaries Ethicon and McNeil); Lederle; Lilly; Miles; Parke-Davis; Pfizer; Purdue Frederick; Quad; Roche; Schering; Upjohn; and Wyeth-Ayerst. Distribution within Panama will be supervised by Gasper Garcia de Paredes, a former minister of health. Project HOPE, located in Millwood, Va., has sponsored medical education programs in Panama since the early 1980s. The Connecticut-based relief organization AmeriCares is targeting a second round of shipments to Rumania for late in the week of Jan. 15. The group sent about $1.4 mil. in drugs and medical supplies to that country Jan. 5. AmeriCares solicited industry contributions following a request from the Knights of Malta, a Catholic humanitarian organization, an AmeriCares spokesman said. Products donated include antibiotics, analgesics, anti-bacterials and pediatric vitamins and infant formula. White House physician Burton Lee, a long-time AmeriCares volunteer, was among medical personnel accompanying the shipment. The 25 companies assisting in the AmeriCares effort include: Abbott; Astra Pharmaceuticals; Bristol-Myers Squibb; Copley Pharmaceuticals; Merck; McNeil; Pal Pac; Purdue Frederick; Stuart; and Upjohn. Many of these are expected to participate in the second shipment to Rumania, together with additional companies, the spokesman said. The second shipment also is expected to total about $1.4 in donations. AmeriCares also coordinated donations to Panama in late December.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth